Debevoise Advises Precision Medicine Group in New $275 Million Investment

2 January 2018

Debevoise & Plimpton LLP successfully advised Precision Medicine Group on a new $275 million investment, led by Berkshire Partners and TPG Growth, alongside a significant participation from Precision’s co-founders and management team and original investors Oak Investment Partners and J.H. Whitney.

Formed in 2011, Precision Medicine Group is a specialized services company supporting next generation approaches to drug development and commercialization. Precision provides an integrated infrastructure that supports pharmaceutical and life sciences companies as they develop new products in the age of precision medicine. The company is headquartered in Bethesda, Maryland with offices throughout North America and Europe.

The Debevoise team is led by partners is led by partner E. Raman Bet-Mansour and includes partners Gary M. Friedman and Rafael Kariyev, counsel Christopher Rosekrans, Charles E. Wachsstock and Krya Bromley and associates David M. Becker, David P. Iozzi, Vikas Mehta and Marina Capeto Novello.

Debevoise & Plimpton LLP is a premier law firm with market-leading practices, a global perspective and strong New York roots. We deliver effective solutions to our clients’ most important legal challenges, applying clear commercial judgment and a distinctively collaborative approach.